Tongfang Kontafarma Holdings Limited Logo

Tongfang Kontafarma Holdings Limited

1312.HK

(1.0)
Stock Price

0,03 HKD

-4.04% ROA

-5.4% ROE

-3.84x PER

Market Cap.

223.148.480,00 HKD

26.75% DER

0% Yield

-3.99% NPM

Tongfang Kontafarma Holdings Limited Stock Analysis

Tongfang Kontafarma Holdings Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Tongfang Kontafarma Holdings Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.18x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock maintains a fair debt to equity ratio (54%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

The stock's ROE indicates a negative return (-9.57%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-7.67%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-2), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Tongfang Kontafarma Holdings Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Tongfang Kontafarma Holdings Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Tongfang Kontafarma Holdings Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Tongfang Kontafarma Holdings Limited Revenue
Year Revenue Growth
2010 451.444.000
2011 725.298.000 37.76%
2012 704.698.000 -2.92%
2013 703.468.000 -0.17%
2014 733.125.000 4.05%
2015 465.739.000 -57.41%
2016 633.279.000 26.46%
2017 1.344.336.000 52.89%
2018 2.093.724.000 35.79%
2019 1.482.347.000 -41.24%
2019 1.482.347.000 0%
2020 1.009.134.000 -46.89%
2021 961.089.000 -5%
2022 894.062.000 -7.5%
2023 809.107.000 -10.5%
2024 1.834.068.000 55.88%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Tongfang Kontafarma Holdings Limited Research and Development Expenses
Year Research and Development Expenses Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 4.470.000 100%
2017 23.727.000 81.16%
2018 25.283.000 6.15%
2019 0 0%
2019 33.706.000 100%
2020 35.705.000 5.6%
2021 45.633.000 21.76%
2022 29.110.000 -56.76%
2023 20.750.000 -40.29%
2024 16.316.000 -27.18%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Tongfang Kontafarma Holdings Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2010 17.753.000
2011 35.577.000 50.1%
2012 38.561.000 7.74%
2013 42.164.000 8.55%
2014 47.152.000 10.58%
2015 60.842.000 22.5%
2016 100.491.000 39.46%
2017 138.808.000 27.6%
2018 156.275.000 11.18%
2019 157.998.000 1.09%
2019 157.998.000 0%
2020 139.667.000 -13.12%
2021 132.686.000 -5.26%
2022 115.331.000 -15.05%
2023 113.023.000 -2.04%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Tongfang Kontafarma Holdings Limited EBITDA
Year EBITDA Growth
2010 532.570.000
2011 141.965.000 -275.14%
2012 95.346.000 -48.89%
2013 75.392.000 -26.47%
2014 79.846.000 5.58%
2015 11.843.000 -574.2%
2016 20.816.000 43.11%
2017 116.731.000 82.17%
2018 281.801.000 58.58%
2019 380.201.000 25.88%
2019 466.198.000 18.45%
2020 186.171.000 -150.41%
2021 102.577.000 -81.49%
2022 83.682.000 -22.58%
2023 -58.998.000 241.84%
2024 233.436.000 125.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Tongfang Kontafarma Holdings Limited Gross Profit
Year Gross Profit Growth
2010 51.848.000
2011 111.845.000 53.64%
2012 58.831.000 -90.11%
2013 70.556.000 16.62%
2014 70.086.000 -0.67%
2015 24.202.000 -189.59%
2016 94.119.000 74.29%
2017 336.875.000 72.06%
2018 562.998.000 40.16%
2019 748.707.000 24.8%
2019 748.707.000 0%
2020 555.749.000 -34.72%
2021 482.889.000 -15.09%
2022 506.221.000 4.61%
2023 464.544.000 -8.97%
2024 1.095.536.000 57.6%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Tongfang Kontafarma Holdings Limited Net Profit
Year Net Profit Growth
2010 168.332.000
2011 76.158.000 -121.03%
2012 26.834.000 -183.81%
2013 32.564.000 17.6%
2014 17.280.000 -88.45%
2015 -34.237.000 150.47%
2016 -37.076.000 7.66%
2017 -1.806.000 -1952.93%
2018 32.499.000 105.56%
2019 65.211.000 50.16%
2019 65.211.000 0%
2020 -20.085.000 424.68%
2021 -4.553.000 -341.14%
2022 -109.744.000 95.85%
2023 -28.843.000 -280.49%
2024 18.980.000 251.97%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Tongfang Kontafarma Holdings Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Tongfang Kontafarma Holdings Limited Free Cashflow
Year Free Cashflow Growth
2010 16.094.000
2011 -34.985.000 146%
2012 -108.072.000 67.63%
2013 -93.275.000 -15.86%
2014 -40.426.000 -130.73%
2015 -29.335.000 -37.81%
2016 -37.586.000 21.95%
2017 -138.645.000 72.89%
2018 -18.797.000 -637.59%
2019 -64.572.000 70.89%
2019 -16.143.000 -300%
2020 26.030.000 162.02%
2021 -49.315.000 152.78%
2022 -53.844.000 8.41%
2023 11.734.500 558.85%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Tongfang Kontafarma Holdings Limited Operating Cashflow
Year Operating Cashflow Growth
2010 115.805.000
2011 -7.609.000 1621.95%
2012 45.311.000 116.79%
2013 -64.462.000 170.29%
2014 -8.130.000 -692.89%
2015 -14.735.000 44.83%
2016 12.432.000 218.52%
2017 -47.262.000 126.3%
2018 66.864.000 170.68%
2019 25.670.000 -160.48%
2019 6.417.500 -300%
2020 206.933.000 96.9%
2021 75.068.000 -175.66%
2022 -2.165.000 3567.34%
2023 14.898.500 114.53%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Tongfang Kontafarma Holdings Limited Capital Expenditure
Year Capital Expenditure Growth
2010 99.711.000
2011 27.376.000 -264.23%
2012 153.383.000 82.15%
2013 28.813.000 -432.34%
2014 32.296.000 10.78%
2015 14.600.000 -121.21%
2016 50.018.000 70.81%
2017 91.383.000 45.27%
2018 85.661.000 -6.68%
2019 90.242.000 5.08%
2019 22.560.500 -300%
2020 180.903.000 87.53%
2021 124.383.000 -45.44%
2022 51.679.000 -140.68%
2023 3.164.000 -1533.34%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Tongfang Kontafarma Holdings Limited Equity
Year Equity Growth
2010 646.851.000
2011 994.019.000 34.93%
2012 1.161.064.000 14.39%
2013 1.210.308.000 4.07%
2014 1.713.749.000 29.38%
2015 1.608.605.000 -6.54%
2016 1.643.063.000 2.1%
2017 1.848.712.000 11.12%
2018 1.909.061.000 3.16%
2019 1.921.048.000 0.62%
2020 1.353.757.000 -41.9%
2021 1.337.784.000 -1.19%
2022 1.156.281.000 -15.7%
2023 1.061.946.000 -8.88%
2023 1.140.541.000 6.89%
2024 1.060.731.000 -7.52%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Tongfang Kontafarma Holdings Limited Assets
Year Assets Growth
2010 1.426.535.000
2011 1.587.749.000 10.15%
2012 1.611.846.000 1.49%
2013 1.625.996.000 0.87%
2014 2.426.774.000 33%
2015 2.629.925.000 7.72%
2016 3.154.191.000 16.62%
2017 3.444.210.000 8.42%
2018 3.342.464.000 -3.04%
2019 4.000.172.000 16.44%
2020 2.542.284.000 -57.35%
2021 2.558.775.000 0.64%
2022 2.120.443.000 -20.67%
2023 1.727.335.000 -22.76%
2023 1.827.373.000 5.47%
2024 1.691.887.000 -8.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Tongfang Kontafarma Holdings Limited Liabilities
Year Liabilities Growth
2010 779.684.000
2011 593.730.000 -31.32%
2012 450.782.000 -31.71%
2013 415.688.000 -8.44%
2014 713.025.000 41.7%
2015 1.021.320.000 30.19%
2016 1.511.128.000 32.41%
2017 1.595.498.000 5.29%
2018 1.433.403.000 -11.31%
2019 2.079.124.000 31.06%
2020 1.188.527.000 -74.93%
2021 1.220.991.000 2.66%
2022 964.162.000 -26.64%
2023 665.389.000 -44.9%
2023 686.832.000 3.12%
2024 631.156.000 -8.82%

Tongfang Kontafarma Holdings Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.26
Net Income per Share
-0.01
Price to Earning Ratio
-3.84x
Price To Sales Ratio
0.15x
POCF Ratio
7.83
PFCF Ratio
48.88
Price to Book Ratio
0.21
EV to Sales
0.3
EV Over EBITDA
-23.57
EV to Operating CashFlow
15.41
EV to FreeCashFlow
96.19
Earnings Yield
-0.26
FreeCashFlow Yield
0.02
Market Cap
0,22 Bil.
Enterprise Value
0,44 Bil.
Graham Number
0.21
Graham NetNet
-0.04

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
-0.99
ROE
-0.05
Return On Assets
-0.03
Return On Capital Employed
-0.14
Net Income per EBT
0.7
EBT Per Ebit
0.46
Ebit per Revenue
-0.12
Effective Tax Rate
-0.33

Margins

Sales, General, & Administrative to Revenue
0.06
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.58
Operating Profit Margin
-0.12
Pretax Profit Margin
-0.06
Net Profit Margin
-0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.01
Free CashFlow per Share
0
Capex to Operating CashFlow
0.84
Capex to Revenue
0.02
Capex to Depreciation
0.23
Return on Invested Capital
-0.18
Return on Tangible Assets
-0.04
Days Sales Outstanding
93.51
Days Payables Outstanding
4.17
Days of Inventory on Hand
54.93
Receivables Turnover
3.9
Payables Turnover
87.59
Inventory Turnover
6.65
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,19
Tangible Book Value per Share
0.14
Shareholders Equity per Share
0.19
Interest Debt per Share
0.06
Debt to Equity
0.27
Debt to Assets
0.17
Net Debt to EBITDA
-11.59
Current Ratio
1.45
Tangible Asset Value
0,81 Bil.
Net Current Asset Value
-0,04 Bil.
Invested Capital
972843000
Working Capital
0,18 Bil.
Intangibles to Total Assets
0.15
Average Receivables
0,36 Bil.
Average Payables
0,01 Bil.
Average Inventory
94760500
Debt to Market Cap
1.28

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Tongfang Kontafarma Holdings Limited Dividends
Year Dividends Growth
2012 0
2013 0 0%

Tongfang Kontafarma Holdings Limited Profile

About Tongfang Kontafarma Holdings Limited

Tongfang Kontafarma Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs and laboratory related products in Mainland China, Singapore, Taiwan, and the United States. The company operates in Pharmaceutical Business and Fitness Business segments. It also offers chemical drugs and prescribed traditional Chinese medicines; operates fitness centers; operates in the franchise business; and provides consultation services for fitness and health activities. The company trades in laboratory related products; researches and develops medical products; and offers corporate advisory services. As of December 31, 2021, it operated 12 fitness centers and 2 yoga center in Taiwan; and 10 fitness centers in Singapore. The company was formerly known as Allied Cement Holdings Limited and changed its name to Tongfang Kontafarma Holdings Limited in August 2016. The company was founded in 1993 and is headquartered in Wan Chai, Hong Kong. Tongfang Kontafarma Holdings Limited is a subsidiary of China Health Management Investment Limited.

CEO
Mr. Feifei Wang
Employee
717
Address
Sun Hung Kai Centre
Wan Chai,

Tongfang Kontafarma Holdings Limited Executives & BODs

Tongfang Kontafarma Holdings Limited Executives & BODs
# Name Age
1 Mr. Jiankun Liu
Executive Director
70
2 Ms. Lok Tung Chan
Company Secretary
70
3 Mr. Feifei Wang
Executive Chairman & President
70
4 Ms. Linna Qiao
Vice President & Executive Director
70
5 Ms. Zixiu Guo
Financial Controller & Executive Director
70
6 Mr. Jie Zhang
Chief Operating Officer
70

Tongfang Kontafarma Holdings Limited Competitors